We have to look at patients holistically, who have kidney disease and diabetes, to address the totality of risks, certainly progression to kidney failure, but also prevention of cardiovascular events and deaths. Ozempic and other GLP-1s will be compared to another diabetes drug class, SGLT-2 inhibitors Given Ozempics reduction of kidney disease events in the FLOW study, it seems likely that the GLP-1s will be used together with and compared against SGLT-2 inhibitor drugs
Log in This article is exclusive to STAT+ subscribers Unlock this article plus daily intelligence on Capitol Hill and the life sciences industry by subscribing to STAT+
If gastrointestinal side effects are prominent, oral rehydration solutions may be beneficial
In the Phase 3 Tesamorelin trials, lean body mass increased by a mean of 0.41.2 kg
Gastroparesis, also known as stomach paralysis, is a condition in which the stomach empties very slowly
Therefore, when developing our products, we are committed to responsible manufacturing processes and carefully selected ingredients